Updated CKD Guidelines Promote Cystatin C, Risk Equations, and SGLT2 Inhibitors

(MedPage Today) — Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization’s updated clinical practice guideline.
In a synopsis of the recently published guideline — serving…

Source link : https://www.medpagetoday.com/nephrology/generalnephrology/114580

Author :

Publish date : 2025-03-10 21:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Updated CKD Guidelines Promote Cystatin C, Risk Equations, and SGLT2 Inhibitors

TYK2 Inhibitor Scores Two Wins Outside Plaque Psoriasis

Major ship collision in UK waters sparks fears of toxic chemical leak

Related Posts

FDA Approves Mepolizumab for COPD

Funding for 988 Crisis Line Holding Steady for Now

EMA Changes Azithromycin Use to Combat Antibiotic Resistance

Niraparib Shows Mixed Signals in Early Prostate Cancer Treatment

EMA Recommends Treatment for Maple Syrup Urine Disease

MedPod Today: Alzheimer’s Blood Test; Vax Claims Debunked; Top GLP-1 for Weight Loss

FDA Approves Mepolizumab for COPD

Funding for 988 Crisis Line Holding Steady for Now

EMA Changes Azithromycin Use to Combat Antibiotic Resistance

Niraparib Shows Mixed Signals in Early Prostate Cancer Treatment

EMA Recommends Treatment for Maple Syrup Urine Disease

MedPod Today: Alzheimer’s Blood Test; Vax Claims Debunked; Top GLP-1 for Weight Loss

‘Most Favored Nation’ Drug Pricing Is the Headline — But the Real Crisis Runs Deeper

Trump’s Budget Bill Includes Medicaid Work Requirement, Limits Transgender Care

Categories

Archives